CD8A and cancer: IL-6 inhibition does not inhibit CD8-positive T cells, which has an antitumor effect; thus, IL-6 is thought to have less effect than ICIs on malignant tumors.[22] Accordingly, IL-6 receptor antagonists might be effective against irAEs.